Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare Nautilus Biotechnology to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk.
This is a breakdown of current ratings and recommmendations for Nautilus Biotechnology and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nautilus Biotechnology Competitors||318||1316||1817||57||2.46|
Insider & Institutional Ownership
47.9% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 61.3% of shares of all “Analytical instruments” companies are owned by institutional investors. 13.3% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Nautilus Biotechnology and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nautilus Biotechnology Competitors||-187.73%||3.44%||-10.22%|
Valuation & Earnings
This table compares Nautilus Biotechnology and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nautilus Biotechnology||N/A||-$50.31 million||-6.05|
|Nautilus Biotechnology Competitors||$1.19 billion||$356.47 million||-7.82|
Nautilus Biotechnology’s rivals have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Nautilus Biotechnology rivals beat Nautilus Biotechnology on 8 of the 12 factors compared.
Nautilus Biotechnology Company Profile (Get Rating)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.